Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies and a primary focus on commercialization.  The corporate strategy is to bring products to market as quickly as possible and use the proceeds to further the development and commercialization of the remaining technologies.  In addition to marketed products based on the ProBiora3 technology, the Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.  Oragenics has developed platform technologies with respect to its products, thereby creating a potential pipeline of future products, which the Company expects to develop.